絞り込み

16633

広告

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system.

著者 Ji Z , Peng Z , Gong J , Zhang X , Li J , Lu M , Lu Z , Shen L
BMC Cancer.2019 Jul 17 ; 19(1):705.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (6view , 0users)

Full Text Sources

Immune checkpoint inhibitors (ICIs) were approved to have a significant antitumor activity in various tumor types. In practice, some patients do not seem to benefit from ICIs but rather to have accelerating disease. The aim of this study was to evaluate hyperprogression in patients with malignant tumors of digestive system treated with ICIs.
PMID: 31315610 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード